ANI Pharmaceuticals Inc

ANIP is clearly in Stage 4 – Decline with strong medium-term bearish conditions and favorable short-term sell timing as price trades below key EMAs with no signs of exhaustion. Execution posture is to sell now into any minor strength, maintaining discipline within the downtrend while preserving potential long-term structural upside.

• ↑Q1 2026 revenue $237.5M (+20% YoY); 2026 guidance $1.08–1.14B
• ↑Cortrophin Gel revenue up 42% to $75.1M, addressing 285K-patient market
• ↓Medicare Part D access hurdles limit revenue from retina therapies